Features | Partner Sites | Information | LinkXpress
Sign In
Ampronix
GLOBETECH PUBLISHING LLC
Schiller

Hidden Data Behind Imaging Scans for Cancer May offer New Radiotherapy Strategies

By Medimaging International staff writers
Posted on 30 Jul 2014
Information hidden in imaging tests could help clinicians more effectively choose the radiation therapy dose needed to kill tumors, suggests a study of more than 300 cancer patients.

The research, to be presented at the 56th annual meeting of the American Association of Physicists in Medicine (AAPM), held during July 28 to August 1, 2014, in Austin, TX, USA, is the largest study to date to use radiomics—extracting statistical data from images and other measurements—to help predict the probable progression of cancer or its response to treatment based on positron emission tomography (PET) imaging scans of patients with non-small-cell lung cancer and head and neck cancer.

“Currently, there is a one-size-fits-all process for selecting radiation therapy doses, which might be too much for some patients and not enough for others,” said Joseph Deasy, PhD, senior author of the study and chair of the department of medical physics at Memorial Sloan-Kettering Cancer Center (New York, NY, USA). “Radiomics will help us know when we can turn down the treatment intensity with confidence, knowing we can still control the disease.”

In the study, researchers performed PET scanning in 163 non-small-cell lung cancer patients and 174 head and neck cancer patients before and after treatment. They extracted a range of information from each tumor, including the intensity value of the PET image, the roughness of the image, and other information, such as how round the tumor was. In PET, the brighter an area is, the higher the intensity, revealing that the tumor is consuming a greater amount of energy from the injected radioactive glucose substitute tracer.

Comparing the data gathered from the before and after scans to how the patient fared—including whether the tumor shrank or how long the patient survived—researchers can create models that will help direct future therapy. In this study, for instance, researchers determined that lung tumors that have a higher uptake of the tracer need to be treated with a higher dose of radiation than is typically prescribed.

“Standard protocol today is to only use PET imaging to define the extent of a tumor to be treated,” said Dr. Deasy. “Based on the information from this study, the data would be extracted from those images and put into models that would tell the physician what dose was required to kill the tumor with a high probability.” He noted that radiomics is a team effort that requires good collaboration between physicians, physicists, and computer scientists.

Related Links:

Memorial Sloan-Kettering Cancer Center



Channels

Radiography

view channel
Image: Fujifilm\'s Aspire Cristalle (Photo courtesy of Business Wire).

Diagnostic Imaging Solutions Provider Submits Mammography Upgrade for FDA Approval

A leading provider of medical informatics solutions and diagnostic imaging products has submitted the first of several modules of its Digital Breast Tomosynthesis (DBT) upgrade for its mammography system,... Read more

Ultrasound

view channel

New Ultrasound System Enhances Patient Care and User Experience

A new ultrasound system with innovative specialized transducers and improved image quality, intended for general imaging, women’s health, and shared service applications, has been announced. The system features improved accuracy, performance, assessment tools, advanced automation, and an enhanced user experience.... Read more

Nuclear medicine

view channel

Clinical Study Shows Added Value of Amyloid PET Imaging in the Diagnosis and Treatment of Dementia

Early-onset dementia patients could benefit from a new PET imaging agent developed by a major medical imaging vendor. The results of a clinical study showing the effectiveness of the amyloid PET imaging agent were presented at the Alzheimer’s Association International Conference (AAIC 2015) in Washington DC (USA).... Read more

General/Advanced Imaging

view channel
Image: Illustration of a new technique using Optical Coherence Tomography that could help surgeons differentiate a human brain tumor, red, from surrounding noncancerous tissue, green (Photo courtesy of  Carmen Kut, Jordina Rincon-Torroella, Xingde Li and Alfredo Quinones-Hinojosa/Johns Hopkins Medicine).

Imaging Technique Helps Safer and More Effective Removal of Brain Tumors

Researchers at the Johns Hopkins University have demonstrated a new imaging technology that could enable neurosurgeons to better differentiate between healthy and cancerous brain tissue and perform safer... Read more

Industry News

view channel

Guerbet Aims for Global Medical Imaging Leadership by Acquisition of Mallinckrodt’s CMDS Business

Guerbet (Paris, France) has announced a definitive agreement for the acquisition of the Contrast Media and Delivery Systems (CMDS) business of pharmaceutical giant Mallinckrodt (Chesterfield, Derbyshire, UK). The acquisition gave Guerbet and the CMDS unit combined pro-forma sales of nearly EUR 800 million in 2014, a... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.